Details
Stereochemistry | ACHIRAL |
Molecular Formula | C32H35N7O4 |
Molecular Weight | 581.6648 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1N=CC2=C1NC3=CC=CC=C3N(C2)C(=O)C4=CC(C)=C(CNC(=O)N5CCN(CC6=CC(O)=CC(O)=C6)CC5)C=C4
InChI
InChIKey=HWPGRFRXZNLZEX-UHFFFAOYSA-N
InChI=1S/C32H35N7O4/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43)
Molecular Formula | C32H35N7O4 |
Molecular Weight | 581.6648 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/19615387Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/22420322 | https://www.ncbi.nlm.nih.gov/pubmed/25761839
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19615387
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/22420322 | https://www.ncbi.nlm.nih.gov/pubmed/25761839
WAY 267464 dihydrochloride is a potent and selective agonist at the oxytocin receptor (OTR). WAY 267464 has been shown to cross the blood-brain-barrier to a significantly greater extent than exogenously applied oxytocin. WAY 267464 dose-dependently reduced anxiety on the four-plate test and prevented the deficits in prepulse inhibition induced by MK-801 or amphetamine. The ability of WAY 267464 to function as a V1AR antagonist may limit its potential therapeutic use in humans, as it would conceivably prevent the improvements in social behavior and social cognition that may be assumed to arise from a primary OTR agonist action.
CNS Activity
Originator
Sources: https://www.google.com/patents/US20070117794
Curator's Comment: # Wyeth Research
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2049 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19615387 |
58.4 nM [Ki] | ||
Target ID: CHEMBL1889 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22420322 |
113.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. | 2008 |
|
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. | 2010 Jan |
|
Non-peptide oxytocin receptor ligands and hamster circadian wheel running rhythms. | 2014 Oct 17 |
|
A non-peptide oxytocin receptor agonist, WAY-267,464, alleviates novelty-induced hypophagia in mice: insights into changes in c-Fos immunoreactivity. | 2014 Sep |
|
WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. | 2015 Aug |
|
Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. | 2016 Jan 27 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22420322
Rats: 10 and 100 mg/kg
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22420322
Functional response of the receptors were measured with luciferase reporter assays, based on the downstream activation, following agonist treatment, of the NFAT response element that has been additionally expressed in those cells as a fusion to the luciferase gene. For the OTR, oxytocin had a functional EC50 of 9.0 nM and WAY 267,464 showed weaker activity, with an observed EC50 of 881 nM. Oxytocin generated a functional response at the V1aR with an EC50 of 59.7 nM, whereas WAY 267,464 did not activate the receptor at concentrations as high as 100 uM. The EC50 of a vasopressin control at the V1aR was measured to be 13.5 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:06:04 GMT 2023
by
admin
on
Sat Dec 16 18:06:04 GMT 2023
|
Record UNII |
XXL55X3DKM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
WAY-267464
Created by
admin on Sat Dec 16 18:06:04 GMT 2023 , Edited by admin on Sat Dec 16 18:06:04 GMT 2023
|
PRIMARY | |||
|
847375-16-0
Created by
admin on Sat Dec 16 18:06:04 GMT 2023 , Edited by admin on Sat Dec 16 18:06:04 GMT 2023
|
PRIMARY | |||
|
DTXSID30433044
Created by
admin on Sat Dec 16 18:06:04 GMT 2023 , Edited by admin on Sat Dec 16 18:06:04 GMT 2023
|
PRIMARY | |||
|
135506374
Created by
admin on Sat Dec 16 18:06:04 GMT 2023 , Edited by admin on Sat Dec 16 18:06:04 GMT 2023
|
PRIMARY | |||
|
XXL55X3DKM
Created by
admin on Sat Dec 16 18:06:04 GMT 2023 , Edited by admin on Sat Dec 16 18:06:04 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
ANTAGONIST
|
||
|
TARGET -> AGONIST |
|
||
|
SALT/SOLVATE -> PARENT |
|